London & Seattle– Tenpoint Therapeutics, a clinical-stage biotechnology company focused on restoring vision through innovative eye treatments, has appointed Melissa Epperly as Chief Financial Officer. The move comes as the company accelerates preparations for the potential U.S. launch of its lead candidate, BRIMOCHOL™ PF, a therapy aimed at treating presbyopia.
Epperly brings more than 20 years of financial leadership experience in the life sciences sector, having held senior roles in both public and private biopharmaceutical companies. Most recently, she served as CFO of Zentalis Pharmaceuticals, where she led the company through a successful IPO and subsequent fundraising rounds totaling over $1.25 billion. Her career also includes CFO roles at PsiOxus Therapeutics and R-Pharm US, as well as strategic and financial positions at Anchorage Capital, Goldman Sachs, Bain & Company, and Morgan Stanley.
“Melissa brings the vision, energy, and financial firepower we need as we prepare for the launch of BRIMOCHOL™ PF into global markets,” said Henric Bjarke, CEO of Tenpoint Therapeutics. “Her experience navigating capital markets and managing financial operations will be instrumental as we transition to a commercial-stage company.”
In her new role, Epperly will lead Tenpoint’s financial strategy, oversee capital markets activity, and manage operational finance functions. Her appointment is seen as a critical step in scaling the company’s infrastructure as it moves closer to regulatory milestones and potential commercialization.
Currently, Epperly also serves on the boards and audit committees of two Nasdaq-listed biotech firms, Roivant Sciences and Nautilus Biotechnology. She holds an MBA from Harvard Business School and a BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.
“It’s an honor to join Tenpoint at such a defining moment,” said Epperly. “The company’s scientific foundation and bold mission present a powerful opportunity to make a meaningful impact on patients’ lives. I’m excited to help shape the path forward as we advance BRIMOCHOL™ PF and prepare for long-term growth.”
The appointment reflects Tenpoint’s continued momentum in the ophthalmology space as it works to deliver next-generation treatments that address age-related vision loss.
